Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Key Takeaway: Pfizer has announced topline results from a Phase 3 trial of Sigvotatug Vedotin for patients with previously treated metastatic non-squamous non-small cell lung cancer. The details of the results and implications for treatment are currently not disclosed in the article. Further information may be expected in future communications.